{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:10Z","timestamp":1793679190915,"version":"4.5.1"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2019-0428_s_999_w2aab3b7d138b1b6b1aab1c17b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is the most prevalent form of dementia. Currently, the most studied biomarkers of AD are cerebrospinal fluid (CSF) amyloid \u03b2 1-42, total tau and phosphorylated tau. However, misdiagnosis can exceed 20%. Recently, we found that CSF amyloid \u03b2 precursor-like protein-1 (APLP1) and neuronal pentraxin receptor (NPTXR) are promising biomarkers of AD. The aim of the present study is to validate CSF APLP1 and NPTXR as biomarkers of AD severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0428_s_998_w2aab3b7d138b1b6b1aab1c17b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>APLP1 and NPTXR concentrations were measured in the CSF of patients with mild cognitive impairment (MCI) (n\u2009=\u200914), mild AD (n\u2009=\u200921), moderate AD (n\u2009=\u200943) and severe AD (n\u2009=\u200930) using enzyme-linked immunosorbent assays (ELISAs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0428_s_997_w2aab3b7d138b1b6b1aab1c17b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CSF APLP1 and NPTXR were not associated with age or sex. CSF APLP1 was not different between any of the AD severity groups (p\u2009=\u20090.31). CSF NPTXR was significantly different between MCI and mild AD (p\u2009=\u20090.006), mild and moderate AD (p\u2009=\u20090.016), but not between moderate and severe AD (p\u2009=\u20090.36). NPTXR concentration progressively declined from MCI to mild, to moderate and to severe AD patients (p\u2009&lt;\u20090.0001, Kruskal-Wallis test). CSF NPTXR positively correlated with the Mini-Mental Status Examination (MMSE) score (p\u2009&lt;\u20090.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0428_s_996_w2aab3b7d138b1b6b1aab1c17b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NPTXR concentration in CSF is a promising biomarker of AD severity and could inform treatment success and disease progression in clinical settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2019-0428","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T09:02:39Z","timestamp":1565859759000},"page":"1875-1881","source":"Crossref","is-referenced-by-count":28,"title":["Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer\u2019s disease"],"prefix":"10.1515","volume":"57","author":[{"given":"Bryant","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Tsolaki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoninus","family":"Soosaipillai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine , Mount Sinai Hospital , Toronto , ON M5T 3L9 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Biostatistics , Fred Hutchinson Cancer Research Center , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zilakaki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fani","family":"Tagaraki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Fotiou","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effrosyni","family":"Koutsouraki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effrosyni","family":"Grosi","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Prassas","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine , Mount Sinai Hospital , Toronto , ON M5T 3L9 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P.","family":"Diamandis","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada"},{"name":"Department of Pathology and Laboratory Medicine , Mount Sinai Hospital , Toronto , ON M5T 3L9 , Canada"},{"name":"Department of Clinical Biochemistry , University Health Network , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2023033110125144290_j_cclm-2019-0428_ref_001_w2aab3b7d138b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies. Prog Neurobiol 2018;174:53\u201389.","DOI":"10.1016\/j.pneurobio.2018.12.006"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_002_w2aab3b7d138b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Miller JB, Cummings J, Nance C, Ritter A. Neuroscience learning from longitudinal cohort studies of Alzheimer\u2019s disease: lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. Alzheimers Dement 2018;4:350\u20136.","DOI":"10.1016\/j.trci.2018.06.006"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_003_w2aab3b7d138b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018;14:535\u201362.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_004_w2aab3b7d138b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Begcevic I, Brinc D, Brown M, Martinez-Morillo E, Goldhardt O, Grimmer T, et al. Brain-related proteins as potential CSF biomarkers of Alzheimer\u2019s disease: a targeted mass spectrometry approach. J Proteomics 2018;182:12\u201320.","DOI":"10.1016\/j.jprot.2018.04.027"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_005_w2aab3b7d138b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Penke B, Bog\u00e1r F, Paragi G, Gera J, F\u00fcl\u00f6p L. Key peptides and proteins in Alzheimer\u2019s disease. Curr Protein Pept Sci 2019;20: 577\u201399.","DOI":"10.2174\/1389203720666190103123434"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_006_w2aab3b7d138b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292\u2013323.","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_007_w2aab3b7d138b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the early detection and progression of Alzheimer\u2019s disease. Neurotherapeutics 2017;14:35\u201353.","DOI":"10.1007\/s13311-016-0481-z"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_008_w2aab3b7d138b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Begcevic I, Tsolaki M, Brinc D, Brown M, Martinez-Morillo E, Lazarou I, et al. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer\u2019s disease progression. F1000 Research 2018;7:1012.","DOI":"10.12688\/f1000research.15095.1"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_009_w2aab3b7d138b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Schilling S, Mehr A, Ludewig S, Stephan J, Zimmermann M, August A, et al. APLP1 is a synaptic cell adhesion molecule, supporting maintenance of dendritic spines and basal synaptic transmission. J Neurosci 2017;37:5345\u201365.","DOI":"10.1523\/JNEUROSCI.1875-16.2017"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_010_w2aab3b7d138b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer\u2019s disease. Acta Neuropathol 1997;94:519\u201324.","DOI":"10.1007\/s004010050745"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_011_w2aab3b7d138b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J Biol Chem 1997;272:21488\u201394.","DOI":"10.1074\/jbc.272.34.21488"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_012_w2aab3b7d138b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Lee SJ, Wei M, Zhang C, Maxeiner S, Pak C, Calado Botelho S, et al. Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses. J Neurosci 2017;37:1062\u201380.","DOI":"10.1523\/JNEUROSCI.2768-16.2016"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_013_w2aab3b7d138b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Collins MA, An J, Hood BL, Conrads TP, Bowser RP. Label-free LC-MS\/MS proteomic analysis of cerebrospinal fluid identifies protein\/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis. J Proteome Res 2015;14: 4486\u2013501.","DOI":"10.1021\/acs.jproteome.5b00804"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_014_w2aab3b7d138b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics 2015;14:544\u201355.","DOI":"10.1074\/mcp.M114.040576"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_015_w2aab3b7d138b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA, Berven FS. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand 2012;126:90\u20136.","DOI":"10.1111\/ane.12029"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_016_w2aab3b7d138b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 1984;34: 939\u201344.","DOI":"10.1212\/WNL.34.7.939"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_017_w2aab3b7d138b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303\u20138.","DOI":"10.1001\/archneur.56.3.303"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_018_w2aab3b7d138b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342\u20136.","DOI":"10.1021\/ac00028a004"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_019_w2aab3b7d138b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, et al. Identification of longitudinally dynamic biomarkers in Alzheimer\u2019s disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener 2014;9:22.","DOI":"10.1186\/1750-1326-9-22"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_020_w2aab3b7d138b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Schauenburg L, Liebsch F, Eravci M, Mayer MC, Weise C, Multhaup G. APLP1 is endoproteolytically cleaved by \u03b3-secretase without previous ectodomain shedding. Sci Rep 2018;8:1916.","DOI":"10.1038\/s41598-018-19530-8"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_021_w2aab3b7d138b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Sj\u00f6din S, Andersson KK, Mercken M, Zetterberg H, Borghys H, Blennow K, et al. APLP1 as a cerebrospinal fluid biomarker for \u03b3-secretase modulator treatment. Alzheimers Res Ther 2015;7:77.","DOI":"10.1186\/s13195-015-0160-z"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_022_w2aab3b7d138b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, et al. The 28-amino acid form of an APLP1-derived A\u03b2-like peptide is a surrogate marker for A\u03b242 production in the central nervous system. EMBO Mol Med 2009;1:223\u201335.","DOI":"10.1002\/emmm.200900026"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_023_w2aab3b7d138b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer\u2019s disease. Ann Neurol 2007;61:120\u20139.","DOI":"10.1002\/ana.21038"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_024_w2aab3b7d138b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer\u2019s disease in human cerebrospinal fluid. PLoS One 2015;10:e0135365.","DOI":"10.1371\/journal.pone.0135365"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_025_w2aab3b7d138b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer\u2019s disease. Proteomics Clin Appl 2007;1:1373\u201384.","DOI":"10.1002\/prca.200600999"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_026_w2aab3b7d138b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Xiao M-F, Xu D, Craig MT, Pelkey KA, Chien CC, Shi Y, et al. NPTX2 and cognitive dysfunction in Alzheimer\u2019s Disease. Elife 2017;6:e23798.","DOI":"10.7554\/eLife.23798"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_027_w2aab3b7d138b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Yin GN, Lee HW, Cho J-Y, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009;1265:158\u201370.","DOI":"10.1016\/j.brainres.2009.01.058"},{"key":"2023033110125144290_j_cclm-2019-0428_ref_028_w2aab3b7d138b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Schlimgen AK, Helms JA, Vogel H, Perin MS. Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. Neuron 1995;14:519\u201326.","DOI":"10.1016\/0896-6273(95)90308-9"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2019.57.issue-12\/cclm-2019-0428\/cclm-2019-0428.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0428\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0428\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:31:30Z","timestamp":1680262290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0428\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,6,7]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/cclm-2019-0428"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0428","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}